Company / Operating Income
Caribou Biosciences, Inc. Operating Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$148.3M
FY2025
5-year range
-$148.3M / -$34.3M
FY2021-FY2025
Trend
-27.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 4 consecutive years, from -$34M in FY2021 to -$148M in FY2025.
Based on SEC 10-K filings.
-$148M in FY2025.
Declined from -$106M to -$148M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Caribou Biosciences, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 27.8% year-over-year.
- Peak operating income was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$148.3M | -27.8% |
| FY2024 | -$116.1M | -9.1% |
| FY2023 | -$106.4M | -58.9% |
| FY2022 | -$67.0M | -95.2% |
| FY2021 | -$34.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026